Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 513.45 USD 0.24%
Market Cap: 131.8B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one VRTX stock under the Base Case scenario is 285.21 USD. Compared to the current market price of 513.45 USD, Vertex Pharmaceuticals Inc is Overvalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRTX Relative Value
Base Case
285.21 USD
Overvaluation 44%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

11.8
P/S
P/S
Price to Sales
11.8
vs History
15
vs Industry
41
Median 3Y
9.5
Median 5Y
9.5
Industry
7.3
Forward
10.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
6
Median 3Y
25
Median 5Y
25
Industry
21.6
Forward
27.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
6
Median 3Y
20.4
Median 5Y
21.1
Industry
19.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
5
Median 3Y
21.9
Median 5Y
23.1
Industry
24.9
More Details
8
P/B
P/B
Price to Book Value
8
vs History
19
vs Industry
12
Median 3Y
6.2
Median 5Y
6.3
Industry
2.4
More Details
11.1
EV/S
EV/S
Enterprise Value to Sales
11.1
vs History
15
vs Industry
36
Median 3Y
8.4
Median 5Y
8.4
Industry
7.4
Forward
10.1
More Details
12.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
12.9
vs History
14
vs Industry
31
Median 3Y
9.6
Median 5Y
9.6
Industry
9.3
More Details
26.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
26.7
vs History
15
vs Industry
4
Median 3Y
19.7
Median 5Y
19.4
Industry
3.9
Forward
21.1
More Details
27.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
27.9
vs History
15
vs Industry
4
Median 3Y
20.6
Median 5Y
20.4
Industry
3.7
Forward
23.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
5
Median 3Y
17.8
Median 5Y
18.5
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
5
Median 3Y
18.7
Median 5Y
19.9
Industry
3.2
More Details
10.9
EV/IC
EV/IC
Enterprise Value to IC
10.9
vs History
20
vs Industry
23
Median 3Y
9.6
Median 5Y
9.8
Industry
4.3
More Details

Multiples Across Competitors

VRTX Competitors Multiples
Vertex Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.3B USD 11.8 -243.8 26.7 27.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 277 900.2 -172 423.5 -209 377 -206 987.8
US
Abbvie Inc
NYSE:ABBV
372.5B USD 6.6 87.9 17.2 25.9
US
Amgen Inc
NASDAQ:AMGN
168.5B USD 5 41.2 16.6 29.4
US
Gilead Sciences Inc
NASDAQ:GILD
133.4B USD 4.6 277.8 10.9 13.7
US
Epizyme Inc
F:EPE
94.1B EUR 1 941.9 -495.5 -539.6 -525.2
AU
CSL Ltd
ASX:CSL
121.2B AUD 5.1 28.1 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.5B USD 5.1 16.4 10.8 12
US
Seagen Inc
F:SGT
39.3B EUR 18.7 -57.4 -61.7 -55.7
NL
argenx SE
XBRU:ARGX
33.8B EUR 16.9 44.4 328.2 -2 418.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
32.8B USD 14.4 -116.3 -248.9 -169.1
P/S Multiple
Revenue Growth P/S to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/S: 3 298 175.5
11.8
10%
1.2
FR
Pharnext SCA
OTC:PNEXF
36 277 900.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
E
Epizyme Inc
F:EPE
1 941.9
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.7
30%
0.6
NL
argenx SE
XBRU:ARGX
16.9
37%
0.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.4
28%
0.5
P/E Multiple
Earnings Growth PEG
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/E: 82.6
Negative Multiple: -243.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -172 423.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.9
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
277.8
185%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -495.5 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.4 N/A N/A
NL
argenx SE
XBRU:ARGX
44.4
19%
2.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -116.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBITDA: 61.1
26.7
16%
1.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 377 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.6
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -539.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.8
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
NL
argenx SE
XBRU:ARGX
328.2
168%
2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -248.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBIT: 21.8
27.9
15%
1.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -206 987.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.9
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.4
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
10%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 418.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -169.1 N/A N/A

See Also

Summary
VRTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
VRTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VRTX stock valuation using valuation multiples.
Wall Street Estimates
VRTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VRTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 239,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.